Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $25.4444.

A number of brokerages have recently issued reports on ARCT. Citigroup dropped their price objective on Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. B. Riley Financial started coverage on Arcturus Therapeutics in a research note on Wednesday, March 18th. They set a “buy” rating and a $22.00 price target on the stock. Weiss Ratings raised Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, April 21st. Finally, Piper Sandler dropped their price target on Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th.

Arcturus Therapeutics Price Performance

Shares of NASDAQ:ARCT opened at $7.65 on Wednesday. The company has a market capitalization of $217.41 million, a price-to-earnings ratio of -2.72 and a beta of 2.36. The business’s 50-day moving average is $7.97 and its 200-day moving average is $7.41. Arcturus Therapeutics has a 1 year low of $5.85 and a 1 year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. The company had revenue of $2.06 million for the quarter, compared to the consensus estimate of $6.30 million. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%. Analysts anticipate that Arcturus Therapeutics will post -4.24 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. raised its stake in Arcturus Therapeutics by 51.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after buying an additional 738 shares during the period. CANADA LIFE ASSURANCE Co raised its stake in Arcturus Therapeutics by 27.5% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,567 shares during the period. Bank of America Corp DE raised its stake in Arcturus Therapeutics by 0.7% during the 2nd quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company’s stock worth $3,805,000 after buying an additional 2,098 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Arcturus Therapeutics by 42.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,760 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 2,313 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Arcturus Therapeutics by 163.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 2,586 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.